$0.28
−23.81%Price chart
Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 14Sep 18
Key dataSep 18, 2026
Open$0.26
From 52W high−54.10%
Volume4.00
Market cap$31.82M
P/E (TTM)—
P/S (TTM)0.8x
Div yield—
Key dataSep 18, 2026
Open
$0.26
From 52W high
−54.10%
Volume
4.00
Market cap
$31.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
49.6
MomentumView details →
1D Return
−23.81%
YTD Return
+90.28%
SummaryUpdated Jun 1, 2026
OmniAb, Inc. (NASDAQ:OABI) is a biotechnology company founded in 2012 and headquartered in Emeryville, California. The company went public in September 2021 and operates as a platform provider for therapeutic antibody discovery technologies. OmniAb has developed a unique business model centered around genetically modified transgenic animals that produce human-like antibodies, which pharmaceutical and biotechnology companies use to develop new therapeutic drugs. The company has grown from serving 69 partners in 2022 to 95 active partners as of early 2025, with over 375 active programs in its pipeline.
Similar companies
Latest newsMore news →
OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.34d agoOmniAb, Inc. reported financial results for the three and six months ended June 30, 2026, and updated its 2026 financial guidance, increasing revenue and cash outlook based on continued business momentum.45d ago